MedMira Inc (MIR)

MedMira Reports Third Quarter Results FY2026June 29, 2026 8:00 PM
ACCESS NewswireHALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2026.Corporate updateDuring Q3 FY2026, the Company continued to advance the regulatory approval process for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). The Company received its initial feedback from Health Canada and remains confident that the new regulatory submission pathway will facilitate more efficient review timelines. Following the quarter, the second phase of clinical trials was completed, and the resulting data will be submitted to support the existing regulatory application. The test is also undergoing evaluation in multiple Canadian provinces to further demonstrate its clinical utility in guiding treatment decisions.The publication of clinical performance data for the Multiplo® TP/nTP has generated increased interest from stakeholders in international markets, including Australia and Latin America. The strong performance of the product further validates the Company's Rapid Vertical Flow (RVF) technology platform and supports future opportunities for specialized diagnostic products.Demand for rapid infectious disease diagnostic tests continued to increase throughout 2026, contributing to broader market opportunities for the Company's products.During the quarter, MedMira also initiated the regulatory approval process for its Health Canada-approved products in Australia under the Mutual Recognition Agreement between Canada and Australia, with similar initiatives underway in selected EMEA markets. These efforts are expected to accelerate market entry, expand the Company's international presence, and support long-term revenue growth.Profit and Loss HighlightsRevenue: The Company recorded revenues in Q3 FY2026 of $241,189 compared to Q2 FY2026 $24,503 and $59,117 in the same period last year. The Company recorded higher revenue due to sales in products and service revenue.Gross Profit: The Company recorded a gross profit in Q2 FY2026 of $176,409 compared to $18,132 in Q2 FY2026 and $43,011 in the same period last year.Operating expenses: The Company recorded for this quarter operating expenses of $441,218 compared to $423,180 in Q2 FY2026 and $772,776 in the same period last year.Net loss: The Company recorded a net loss in Q3 FY2026 of $483,660 compared to a net loss of $657,552 for the quarter last year.Balance Sheet HighlightsAssets: The Company recorded decreased of its assets by $176,935 between Q2 FY2026 and Q3 FY2026 which was mainly due to depreciation expense on its corporate assets.Liabilities: The Company's liabilities increased by $306,725 between Q2 FY2026 and Q3 FY2026. The Company's current liabilities increased by $263,164 which was mainly due to an increase in accounts payable and accrued liabilities.Loans in default decreased by $9,522 due to the fluctuations in the United States Dollar and the Swiss Franc. All long and short terms debts are currently under negotiation to restructure terms and conditions of repayment.Working Capital deficit: As a result of the changes noted above, the Company recorded a higher working capital deficit of $365,147 or an increase of 2% compared to last quarter.The Company's financial statements and management's discussion and analysis are available on the Company's profile on SEDAR at www.sedar.com. For matters of going concern, reference is made to the Auditor's Emphasis of Matter statement in the fiscal year ended 2025 Auditors Report and note 2b in the audited financial statements which are also available on SEDAR.About MedMiraMedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.MedMira Contacts:Markus Meile, CFO
Tel: 902-450-1588
Email: ir@medmira.comSOURCE: MedMira, Inc.View the original press release on ACCESS NewswireOriginal: MedMira Reports Third Quarter Results FY2026

MedMira Reports Second Quarter Results FY2025April 1, 2026 10:00 PM
ACCESS NewswireHALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026.Corporate updateIn Q2 FY2026, the Company signed a distribution agreement with McKesson, the world's second largest wholesalers in health care. This partnership allows MedMira to reach more customers and benefit from an excellent service and network provided by a leading supplier of medical and surgical products in North America. McKesson's Medical-Surgical Supplies division serves over 200,000 customers and provides in 95% of US locations next-day delivery. As a result, MedMira is able to expand its access to private, state and federal clients to continuously grow its sales and brand recognition.The product offering through McKesson USA is for all of MedMira's FDA approved products and its Miriad product line (RUO). In Canada, McKesson Canada offers all of the Company's Health Canada approved products such as the Multiplo® TP/HIV rapid test.In Q2 FY2026, the results of the first phase of the clinical trials of MedMira's Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) were published by the BMC Infectious Diseases Journal accessible at: https://pubmed.ncbi.nlm.nih.gov/41361278/.The study not only outlined the high sensitivity and specificity of MedMira's Multiplo® TP/nTP, it also showcased the need for a new generation of rapid test that provide an immediate answer to treat or not treat (medical stewardship). The data published has been submitted to Health Canada for review.At the same time, clinical trials for MedMira's Multiplo® TP/HIV self-test have steadily progressed to achieve the required number for regulatory approval in Canada. At the time regulatory approval can be obtained, MedMira will offer the first TP/HIV self-test solution in Canada.Subsequent to Q2 FY2026, the Company has continued to work on the commercial version of MedMira's unique MiROQ technology. MedMira's patented novel diagnostic system allows for accessible and efficient diagnostic tools for quantitative results in minutes. Whereas the development of the prototype is ongoing, a first version of the supporting software solution has been developed.Profit and Loss HighlightsRevenue: The Company recorded revenues in Q2 FY2026 of $24,503 compared to Q1 FY2026 $54,208 and $69,001 in the same period last year. The Company recorded significantly lower revenue during the months of November and December 2025. This is due to delay in sales orders mainly associated with the government shutdown that had a negative after effect on the ordering process. As of Q3 FY2026, this situation has been stabilized.Gross Profit: The Company recorded a gross profit in Q2 FY2026 of $18,132 compared to $42,300 in Q1 FY2026 and $45,643 in the same period last year.Operating expenses: The Company recorded for this quarter operating expenses of $423,180 compared to $635,122 in Q1 FY2026 and $1,141,481 in the same period last year. Due to the reduced sales, the Company adjusted its operating expenses to counter-act on the temporary sales reduction.Net loss: The Company recorded a net loss in Q2 FY2025 of $1,199,918 compared to a net loss of $590,789 for the quarter last year.Balance Sheet HighlightsAssets: The Company recorded decreased of its assets by $18,213 between Q1 FY2026 and Q2 FY2026 which was due to an increase of cash offset by depreciation of the corporate assets.Liabilities: The Company's liabilities increased by $639,339 between Q1 FY2026 and Q2 FY2026. The Company's current liabilities increased by $623,180 which was mainly due to an increase in accounts payable and accrued liabilities.Loans in default increased by $201,541 due to the fluctuations in the United States Dollar and the Swiss Franc. All long and short terms debts are currently under negotiation to restructure terms and conditions of repayment.Working Capital deficit: As a result of the changes noted above, the Company recorded a higher working capital deficit of $567,328 or an increase of 2% compared to last quarter.The Company's financial statements and management's discussion and analysis are available on the Company's profile on SEDAR at www.sedar.com. For matters of going concern, reference is made to the Auditor's Emphasis of Matter statement in the fiscal year ended 2025 Auditors Report and note 2b in the audited financial statements which are also available on SEDAR.About MedMiraMedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.MedMira Contacts:
Markus Meile, CFO
Tel: 902-450-1588
Email: ir@medmira.comSOURCE: MedMira, Inc.View the original press release on ACCESS NewswireOriginal: MedMira Reports Second Quarter Results FY2025

MIR under $15

MIR hitting the big time.......NOW HAS SPREAD

mir is creeping like a NUN ---or a church mouse----a promoter with deep pockets

up on hype product --womens infections---Halifax may not be involved-----YET

CO NEEDS gov't money now ---badly

Maybe this news today will get it moving. It’s been a slug for the last 15 months. Can they every have a positive earnings report or some good news??

uP 37 percent a year later than expected---- on no news

come on 17 cents

C'OME on 12 cents

blame it all on John A. MCdonald

https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AAKzDuH.img?h=569&w=799&m=6&q=60&o=f&l=f&x=249&y=75

$mir $0.235 v -0.005 (-2.08%)
Volume: 589,805 @03/19/21 3:59:35 PM EDT

$mir $0.31 ^ 0.02 (6.90%)
Volume: 1,783,894 @02/19/21 3:59:59 PM EST

$mir $0.32 v -0.015 (-4.48%)
Volume: 1,353,810 @02/02/21 3:59:26 PM EST

lower on good volume----pandemic jitters

new day of day trading tommorrow

we get a GODIVA chocolat gift card for every 1000 we buy



https://www.bing.com/th/id/OGC.9dd72a370bd2f0b2f15fdd3b4fa5982e?pid=1.7&rurl=https%3a%2f%2f66.media.tumblr.com%2f383253f80beefd424559564b4b965034%2f729daeeafc2aac56-60%2fs640x960%2fbefec696fcfa5789288fe2518bec4beab0a8f508.gif&ehk=katR2aaZwMyWy297ZK%2bJPU8epNnrU4%2bvfUialSvcS40%3d

$mir $0.24 ^ 0.01 (4.35%)
Volume: 586,601 @01/06/21 3:59:32 PM EST

HAHAHAHAHA---------------------------WHAT----------------A------------BOW-WOW------------ HAHAHAHA----

$mir $0.245 ^ 0.005 (2.08%)
Volume: 684,120 @12/16/20 3:48:26 PM EST

VACCINES have arrived

$mir $0.25 ^ 0.005 (2.04%)
Volume: 662,510 @12/11/20 3:59:59 PM EST

back in ---the 30's

been slip-slydin the last while


https://images.wsdot.wa.gov/nc/002vc08457.jpg

$mir $0.27 ^ 0.04 (17.39%)
Volume: 2,424,435 @11/19/20 3:59:37 PM EST

$mir $0.235 v -0.035 (-12.96%)
Volume: 1,565,293 @11/09/20 3:59:47 PM EST

$mir $0.275 v -0.005 (-1.79%)
Volume: 264,907 @10/30/20 3:58:41 PM EDT

That has nothing to do wit MIR!!!

$mir $.275 ? 0.0 (0.00%)
Volume: 570,308 @10/02/20 3:59:59 PM EDT

$mir $0.28 v -0.005 (-1.75%)
Volume: 363,094 @09/29/20 3:43:21 PM EDT

YUALLS DONT NEED CANUCKLEHEAD STUFF---AT ANY COST

AstraZeneca, which will supply up to 20 million doses of its viral vector vaccine candidate AZD1222.
Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate.
Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate Ad26.COV2.S.
Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate NVX-CoV2373.
Pfizer, which will supply a minimum of 20 million doses of its mRNA vaccine candidate, BNT162. The government is negotiating with the company to expand the agreement to include options for obtaining additional doses.
Moderna, which will supply up to 56 million doseS

Surprised FDA approval is still pending... any second now

Copied from another board...

We had such an incredible afternoon today at MedMira Inc. Laboratory in #ClaytonParkWest!

#MedMira has come out with a patent for #COVID19 that can detect if you have antibodies within minutes, and will show the results for days to follow (which is something that is not common with these types of tests).

Just a few short months ago, 6 months to be exact, MedMira only had 11 staff members. Today, the company has expanded to 54 people! It was truly amazing to see all of their employees who come from over 18 countries; there are 6 summer students and over 30 new immigrants.

The expansion of staff is due to the high demand for their REVEALCOVID-19 TM Total Antibody test.

One of the most valuable things we noticed is that these individuals are extremely hard-working. This job is an exceptional way for them to get the Canadian working experience and to have flourishing and enriching careers!

We felt a true sense of family and community — this is the real beauty of Canada; There is opportunity and space for everyone to work in harmony.

The staff at MedMira contribute a weekly production of over 20,000 COVID-19 tests. We are told that the external performance evaluation of this product in the United States has been exceptional.

They also plan to expand to other markets, such as Europe and Asia.

Please stay tuned for a special feature from my office, highlighting a behind-the-scenes look at MedMira Inc.

Thank you to Hermes Chan (CEO) and Markus Meile (CFO), for your information breakdown of the antibody test. As well as all the exciting things your company is doing and plans to do in the future.

We wish you the best of luck!

Should be a green day today

great advice

Great facebook post by Canadian politician on MIR.v

MedMira has come out with a patent for #COVID19 that can detect if you have antibodies within minutes, and will show the results for days to follow (which is something that is not common with these types of tests).

Just a few short months ago, 6 months to be exact, MedMira only had 11 staff members.

Today, the company has expanded to 54 people! It was truly amazing to see all of their employees who come from over 18 countries; there are 6 summer students and over 30 new immigrants.

https://www.facebook.com/134268600446739/posts/808411506365775/?extid=gZpJa2yakqi1gWjA&d=n

Are we talking about two different companies? Medmira is not Moderna...

Trial enrollment is definitely slowing. Only 2,000 people added this week:
https://www.modernatx.com/cove-study

6500 left until enrollment complete :) 3 weeks/month left? -- MRNA

Nine vaccine developers made a socially positive pledge Tuesday to follow scientific and ethical standards in their development of Covid-19 vaccines, and not to push for rapid regulatory approval or authorization. The pledge, meant to ensure public confidence in the scientific and regulatory process, comes amid growing scepticism of a hastened Covid-19 vaccine. A YouGov poll on September 3 showed that only 42% of Americans would get vaccinated against Covid-19, while 27% said they would not, leaving 31% still uncertain. Three other signatories, Pfizer, BioNTech, and Moderna also have vaccines in phase 3 clinical trials.

Risky?? They have the most accurate and fastest test available and more test than just Covid-19. Every stock has risk, some of the largest names filed for bankruptcy through the years GM, Kmart, JC Penny and so many. Those looking for a sure thing should not play stock market in general. The minor risk with stocks can be offset by great research and knowing what you own. MedMira by my calculations is very safe. Good Luck in all investments

still risky at 30 cents

How is it done?? Once FDA approvals is in... Medmira is off to the races. They have the best Covid-19 test available and the most accurate. They also have test for hiv and others. Very solid here

Stick a fork in it-----ITS DONE

Oncenthey get FDA approval this board will be flooded with people chasing. Best test test available

Investors Load Up... It is coming!!

SOON EVERYONE WILL KNOW Who MedMira is!!! FDA APPROVAL and a FEMA contract will follow quickly after

HUGE GAINS COMING... EASY 10 Bagger with FDA APPROVAL

FDA Approval Soon.. BEST TEST ON THE MARKET!

$mir $0.29 v -0.02 (-6.45%)
Volume: 833,976 @08/27/20 11:57:11 AM EDT

$mir $0.42 ? 0.0 (0.00%)
Volume: 1,415,093 @07/31/20 3:59:49 PM EDT